ESN T
Alternative Names: ESN-TLatest Information Update: 01 Aug 2025
At a glance
- Originator Enveda Biosciences
- Class Anti-inflammatories; Small molecules
- Mechanism of Action Tumour necrosis factor ligand superfamily member 15 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Inflammatory bowel diseases
Most Recent Events
- 24 Jul 2025 Preclinical trials in Inflammatory bowel diseases in USA (PO), before July 2025 (Enveda Biosciences pipeline, July 2025)